|Bid||9.19 x 900|
|Ask||9.21 x 1100|
|Day's Range||8.81 - 9.23|
|52 Week Range||0.25 - 17.49|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 09, 2012|
|1y Target Est||11.67|
Companies at the forefront of coronavirus vaccine research have been a veritable gold mine for investors this year. For example, shares of Moderna (NASDAQ: MRNA) have gained a staggering 278% over the first seven months of 2020, while Novavax's (NASDAQ: NVAX) stock has posted a healthy 3,500% return on investment during this same period. While Heat Biologics (NASDAQ: HTBX) and Vaxart (NASDAQ: VXRT) have both made quantum leaps in terms of their market caps this year, there's a strong chance that each of these lesser-known COVID-19 vaccine stocks may soon be gearing up for another jaw-dropping move higher.
San Francisco, California--(Newsfile Corp. - August 3, 2020) - Hagens Berman urges Vaxart, Inc. (NASDAQ: VXRT) investors who have suffered losses in excess of $50K to submit their losses now. Hagens Berman also encourages persons who may be able to assist the Firm's investigation of possible securities fraud to contact the firm.Relevant Holding Period: Before July 27, 2020Visit: www.hbsslaw.com/investor-fraud/VXRTContact An Attorney Now: VXRT@hbsslaw.com844-916-0895Vaxart, Inc. (VXRT) Investigation:The investigation centers on whether Vaxart misrepresented its ...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc.